Search

In most laboratories dengue antibodies are measured by hemagglutination inhibition (HI), complement fixation (CF), or enzyme-linked immunoassay (ELISA) tests adapted to micromethods. They do not reliably identify the infecting serotype. This paper proposes a description of the modified semi-micro plaque reduction neutralization test used successfully. [ABSTRACT FROM AUTHOR]

Equine influenza (EI) is the main cause of respiratory illness in equines across the globe and is caused by equine influenza A virus (EIV-A), which has impacted the equine industry internationally because of the marginal mortality and high morbidity. In the present study, the immune responses after equine influenza vaccination were evaluated in 4,144 horses in Korea using the hemagglutination inhibition (HI) assay. The equine influenza virus (EIV), A/equine/South Africa/4/03 (H3N8), was used as the antigen in the HI assay. The mean seropositive rates were 89.2% (97.4% in 2016, 77.6% in 2017, and 92.4% in 2018). This paper highlights the advances in understanding the effects of vaccines and control strategies for mitigating the emerging menace by EIV [ABSTRACT FROM AUTHOR]

Biopharmaceutical research often uses a binary "fold-increase" response variable defined by the ratio of a pair of interval-censored measurements taken at baseline and end-of-study. Conventional practice ignores the interval-censoring nature of the data. Moreover, conventional practice dictates that the possible choices for cut-off to define the response must follow a geometric sequence. A novel method based on the "distributional approach" was proposed for the analysis of such paired measurements in a randomized trial context. The degree of fold-increase above which a response is defined can be chosen according to scientific rationale instead of being limited to a geometric sequence. The risk ratio is then estimated for comparison between trial arms. We extend the method to allow for adjustment for baseline covariates in both randomized trial and cohort study settings. The treatment effect is obtained by integrating over the covariate distribution. In the presence of heterogeneity, estimators of the population treatment effect and the average treatment effect are proposed and their performances are evaluated by simulation studies. We apply this method to analyze antibody data measured by the hemagglutination inhibition assay in an influenza study. Supplementary materials for this article are available online. [ABSTRACT FROM AUTHOR]

Copyright of Acta Edulis Fungi is the property of Acta Edulis Fungi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

β-Dystroglycan (β-DG) is a highly glycosylated basement membrane receptor that is cleaved by the proprotein convertase furin, which releases its N-terminal domain (β-DGN). Before cleavage, β-DGN interacts with the glycosyltransferase LARGE1 and initiates functional O-glycosylation of the mucin-like domain of β-DG. Notably, β-DGN has been detected in a wide variety of human bodily fluids, but the physiological significance of secreted β-DGN remains unknown. Here, we show that mice lacking β-DGN exhibit significantly higher viral titers in the lungs after Influenza A virus (IAV) infection (strain A/Puerto Rico/8/1934 H1N1), suggesting an inability to control virus load. Consistent with this, overexpression of β-DGN before infection or intranasal treatment with recombinant β-DGN prior and during infection, significantly reduced IAV titers in the lungs of wild-type mice. Hemagglutination inhibition assays using recombinant β-DGN showed in vitro neutralization of IAV. Collectively, our results support a protective role for β-DGN in IAV proliferation. [ABSTRACT FROM AUTHOR]

Copyright of Avian Diseases is the property of American Association of Avian Pathologists, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

While neutralizing antibody titers measured by hemagglutination inhibition have been proposed as a correlate of protection following influenza vaccination, neutralization alone is a modest predictor of protection against seasonal influenza. Instead, emerging data point to a critical role for additional extra-neutralizing functions of antibodies in protection from infection. Specifically, beyond binding and neutralization, antibodies mediate a variety of additional immune functions via their ability to recruit and deploy innate immune effector function. Along these lines, antibody-dependent cellular cytotoxicity, antibody-mediated macrophage phagocytosis and activation, antibody-driven neutrophil activation, antibody-dependent complement deposition, and non-classical Fc-receptor antibody trafficking have all been implicated in protection from influenza infection. However, the precise mechanism(s) by which the immune system actively tunes antibody functionality to drive protective immunity has been poorly characterized. Here we review the data related to Fc-effector functional protection from influenza and discuss prospects to leverage this humoral immune activity for the development of a universal influenza vaccine. [ABSTRACT FROM AUTHOR]

Haemophilus parasuis (H. parasuis) is a kind of opportunistic pathogen of the upper respiratory tract of piglets. Under certain circumstances, virulent strains can breach the mucosal barrier and enter the bloodstream, causing severe Glässer's disease. Many virulence factors are found to be related to the pathogenicity of H. parasuis strain, but the pathogenic mechanism remains unclear. LuxS/AI-2, as a kind of very important quorum sensing system, affects the growth characteristics, biofilm formation, antibiotic production, virulence, and metabolism of different strains. In order to investigate the effect of luxS/AI-2 quorum sensing system on the virulence of H. parasuis , a deletion mutant strain (ΔluxS) and complemented strain (C-luxS) were constructed and characterized. The results showed that the luxS gene participated in regulating and controlling stress resistance, biofilm formation and virulence. Compared with wild-type strain, ΔluxS strain decreased the production of AI-2 molecules and the tolerance toward oxidative stress and heat shock, and it reduced the abilities of autoagglutination, hemagglutination, and adherence, whereas it increased the abilities to form biofilm in vitro. In vivo experiments showed that ΔluxS strain attenuated its virulence about 10-folds and significantly decreased its tissue burden of bacteria in mice, compared with the wild-type strain. Taken together, the luxS/AI-2 quorum sensing system in H. parasuis not only plays an important role in growth and biofilm formation, but also affects the pathogenicity of H. parasuis. [ABSTRACT FROM AUTHOR]

Copyright of Avian Diseases is the property of American Association of Avian Pathologists, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The objective of this study was to determine the efficacy of the recombinant herpes virus of turkey-Newcastle disease virus (rHVT-NDV) vaccine against Newcastle disease virus (NDV) challenged in 14 days old broiler chickens. One hundred chickens were divided into 5 groups of 20 chickens each. Group 1 chickens received live NDV vaccine via the intra-nasal route. Group 2 chickens received rHVT-NDV vaccine by subcutaneous injection. Group 3 chickens, received both live NDV and rHVT-NDV vaccine. Groups 4 and 5 chickens did not receive any vaccine and served as positive and negative control groups. At 14 days old, all the chickens in Groups 1-4 received virulent NDV challenged by oral drop. The results revealed that the mortality rate of chickens in Groups 1-5 was 50%, 70%, 0%, 100% and 0%, respectively. At 24 days old, the body weight of the surviving chickens in group 1 was the lowest, while the surviving chickens of Groups 2, 3 and 5 were not significantly different (p > 0.05). At 14-day old, antibodies against NDV was detected by hemagglutination-inhibition (HI) test showing that Group 3 had the highest antibody titer level, followed by Group 1, while Group 2 showed a low HI titer similar to non-vaccinated groups. HI test and enzyme-linked immunosorbent assay (ELISA) at 24 days old (10 DPI), increased significantly when compared to those of at 14 days old. In conclusion, the chickens that received live NDV vaccine and was simultaneously vaccinated with rHVT-NDV vaccine at 1 day old, had a higher protection rate than chickens which received either live or recombinant vaccine alone. [ABSTRACT FROM AUTHOR]

Introduction Increasing the immune system's function of fighting infectious diseases is very important in the poultry industry. Ginger, scientifically known as Zingiber officinale, belongs to the Zingiberaceae family. The use of ginger in the diet of poultry increases serum levels of superoxide dismutase enzymes and glutathione peroxidase, which are considered to be important antioxidant enzymes. The main objective of the present study is to evaluate the effect of ginger on the spleen tissue of broiler chickens. Material and Methods The specimens comprised 2 groups of 20 Ross breed broiler chicks, for 42 days and were then, examined and tested. The diet was supplemented with 1 g/kg of ginger powder from the beginning of the rearing period. Blood samples of the chicks were randomly collected to measure the levels of hemagglutination (HI). The removed spleens were fixed with 10% formalin buffer. The specimens were cut in 5-micron diameters and stained with hematoxylin and eosin. Results and Conclusion There was a statistically significant difference in the mean of HI blood titers between the chicks in the growth period and final period groups (p < 0.05). The white-pulp tissue samples were more clearly seen in the treatment group than in the control group, and also, it was observed that the wall of the central artery of the white pulp was thicker in the ginger-treated group as compared with the control group. The nutritional value of ginger may vary. Thus, it is necessary to investigate the effect of this plant final on weight gain; the serum factors associated with the metabolic chart, and the response of the immune system to this plant. [ABSTRACT FROM AUTHOR]

Highlights • Serum collected at hospital admission can be used to assess influenza protection. • There was no trend in antibody among influenza cases by day of collection (0–10). • Inpatients who received influenza vaccination had more antibody than unvaccinated. • Associations between antibody and infection paralleled vaccine effectiveness. Abstract Background Influenza vaccines are important for prevention of influenza-associated hospitalization. However, the effectiveness of influenza vaccines can vary by year and influenza type and subtype and mechanisms underlying this variation are incompletely understood. Assessments of serologic correlates of protection can support interpretation of influenza vaccine effectiveness in hospitalized populations. Methods We enrolled adults hospitalized for treatment of acute respiratory illnesses during the 2014–2015 and 2015–2016 influenza seasons whose symptoms began <10 days prior to enrollment. Influenza infection status was determined by RT-PCR. Influenza vaccination status was defined by self-report and medical record/registry documentation. Serum specimens collected at hospital admission were tested in hemagglutination-inhibition (HAI) and neuraminidase-inhibition (NAI) assays. We evaluated how well antibody measured in these specimens represented pre-infection immune status, and measured associations between antibody and influenza vaccination and infection. Results Serum specimens were retrieved for 315 participants enrolled during the 2014–2015 season and 339 participants during the 2015–2016 season. Specimens were collected within 3 days of illness onset from 65% of participants. Geometric mean titers (GMTs) did not vary by the number of days from illness onset to specimen collection among influenza positive participants suggesting that measured antibody was representative of pre-infection immune status rather than a de novo response to infection. In both seasons, vaccinated participants had higher HAI and NAI GMTs than unvaccinated. HAI titers against the 2014–2015 A(H3N2) vaccine strain did not correlate with protection from infection with antigenically-drifted A(H3N2) viruses that circulated that season. In contrast, higher HAI titers against the A(H1N1)pdm09 vaccine strain were associated with reduced odds of A(H1N1)pdm09 infection in 2015–2016. Conclusions Serum collected shortly after illness onset at hospital admission can be used to assess correlates of protection against influenza infection. Broader implementation of similar studies would provide an opportunity to understand the successes and shortcomings of current influenza vaccines. [ABSTRACT FROM AUTHOR]

Abstract Background Needle-free vaccine delivery systems have many potential advantages including increased vaccine compliance and decreased risk of needlestick injuries and syringe reuse. The Med-Jet® H4 is a gas-powered, auto-disabling disposable syringe jet injector. The Med-Jet family of products are currently being used in dermatology, podiatry, pain management and veterinary practices. The objectives of this study were to assess patient attitudes, time-efficiency, safety and immunogenicity of the seasonal influenza vaccine delivered by Med-Jet compared to the traditional needle-and-syringe. Methods A total of 80 patients were randomized 2:1:1 to receive a commercial trivalent vaccine by Med-Jet or needle injection from a single-dose or multi-dose vial. Patient attitudes were assessed pre-randomization and post-immunization. Safety data were collected for 21 days post-immunization. Efficiency of vaccine administration was measured through a time-and-motion study. Humoral and cellular responses were assessed on Days 0 and 21. Results Overall, the participants readily accepted Med-Jet vaccination despite greater frequency of transient local reactions (eg: redness, swelling) immediately following immunization. Vaccine administration took slightly longer with the Med-Jet, but this difference decreased over time. Geometric mean hemagglutination inhibition titers, seroconversion and seroprotection rates in the Med-Jet and needle groups were equivalent for all influenza strains in the vaccine. Microneutralization responses were also essentially identical. There were no significant differences between the groups in the frequency of functional CD4 + T cells, memory subset distribution or poly-functionality. Conclusions These data suggest that the Med-Jet is an acceptable means of delivering seasonal influenza vaccine. The system was attractive to subjects, rapidly learned by skilled vaccine nurses and elicited both humoral and cellular responses that were indistinguishable from those elicited with needle injection. While other studies have assessed the humoral response to jet injection of influenza vaccine, to our knowledge, this study is the first to assess the cellular aspect of this response. (ClinTrials.gov -NCT03150537). [ABSTRACT FROM AUTHOR]

Abstract Avian influenza in poultry continues to be a great concern worldwide, and the currently licensed inactivated influenza vaccines are not effective against the novel strains of influenza virus that continue to emerge in the field. This warrants the development of more broadly protective influenza vaccines or vaccination regimens. Live attenuated influenza vaccines (LAIVs) and subunit vaccines derived from viral peptides, such as the highly conserved ectodomain of influenza virus matrix protein 2 (M2e), can offer a more broadly reactive immune response. In chickens, we previously showed that a chimeric norovirus P particle containing M2e (M2eP) could provide partial but broad immunity, when administered as a standalone vaccine, and also enhanced the protective efficacy of inactivated vaccine when used in a combination regimen. We also demonstrated that a naturally-selected NS1-truncated H7N3 LAIV (pc4-LAIV) was highly efficacious against antigenically distant heterologous H7N2 low pathogenicity avian influenza virus challenge, especially when used as the priming vaccine in a prime-boost vaccination regimen. In this study, we investigated the cross-subtype protective efficacy of pc4-LAIV in conjunction with M2eP using single vaccination, combined treatment, and prime-boost approaches. Chickens vaccinated with pc4-LAIV showed significant reduction of tracheal shedding of a low pathogenicity H5N2 challenge virus. This cross-subtype protective efficacy was further enhanced, during the initial stages of challenge virus replication, in chickens that received a vaccination regimen consisting of priming with pc4-LAIV at 1 day of age and boosting with M2eP. Further, H5N2-specific serum IgG and pc4-LAIV-specific hemagglutination-inhibition antibody titers were enhanced in LAIV-primed and M2eP boost-vaccinated chickens. Taken together, our data point to the need of further investigation into the benefits of combined and prime-boost vaccination schemes utilizing LAIV and epitope-based vaccines, to develop more broadly protective vaccination regimens. [ABSTRACT FROM AUTHOR]

Abstract Objectives To compare immunogenicity, reactogenicity and acceptability of high- and standard-dose trivalent inactivated influenza vaccine (HDTIV, SDTIV) in 18- to 64-year-olds. Methods We randomized 18- to 64-year-olds to HDTIV or SDTIV in two consecutive years. We collected serum on days 0 and 21, measured haemagglutination inhibition geometric mean titres (GMT) and compared seroconversion, day 21 titres, seroprotection, reactogenicity and acceptability. Results Immunogenicity was evaluable in 42 of 47 2014 participants, all 33 both-year participants and 87 of 90 2015-only participants. First-dose HDTIV recipients experienced seroconversion more frequently than SDTIV recipients to A(H3N2) in 2014 (13/21, 62% vs. 4/21, 19%, p 0.01) and to all vaccine strains in 2015: (A(H1N1): 24/42, 57% vs. 15/59, 25%; A(H3N2): 42/42, 100% vs. 47/59, 80%; B: 25/42, 60% vs. 13/59, 22%; all p <0.01). Day 21 haemagglutination inhibition GMT were higher in first and two sequential-year HDTIV vs. SDTIV recipients: A(H1N1): GMT 749 and 768 vs. 384 (p <0.0001, p 0.002); A(H3N2): 1238 and 956 vs. 633 (p 0.0003, p 0.1); and B: 1113 and 1086 vs. 556 (p 0.0005, p 0.02). HDTIV was more reactogenic (local pain score 3 vs. 1 of 10 on day 0/1, p 0.0003), but recipients were equally willing to be revaccinated (HDTIV: 76/83 (92%); SDTIV: 76/80 (95%), p 0.54). The ratios of day 21 GMT in SDTIV recipients vaccinated in 0 to 4 prior years to those in SDTIV and HDTIV recipients vaccinated in 15 or more prior years were A(H1N1): 3.73 and 1.38; A(H3N2) 3.07 and 1.16; and B: 2.01 and 1.21. Conclusions HDTIV is more immunogenic and reactogenic and as acceptable as SDTIV in 18- to 64-year-olds. [ABSTRACT FROM AUTHOR]

The vast majority of people already have pre-existing immune responses to influenza viruses from one or more subtypes. However, almost all preclinical studies evaluate new influenza vaccine candidates in immunologically naïve animals. Recently, our group demonstrated that priming naive ferrets with broadly reactive H1 COBRA HA based vaccines boosted pre-existing antibodies induced by wild-type H1N1 virus infections. These H1 COBRA HA antigens induced antibodies with HAI activity against multiple antigenically different H1N1 viral variants. In this study, ferrets, preimmune to historical H3N2 viruses, were vaccinated with virus-like particle (VLP) vaccines expressing either an HA from a wild-type H3 influenza virus or a COBRA H3 HA antigen (T6, T7, T10, or T11). The elicited antisera had the ability to neutralize virus infection against a panel of viruses representing vaccine strains selected by the World Health Organization (WHO), or a set of viral variants that co-circulated during the same time period. Preimmune animals vaccinated with H3 COBRA T10 HA antigen elicited sera with higher HAI antibody titers than antisera elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets. However, while the T11 COBRA vaccine did not elicit HAI activity, the elicited antibodies did neutralize antigenically distinct H3N2 influenza viruses. Overall, H3 COBRA-based HA vaccines were able to neutralize both historical H3 and comtemporary, as well as future H3N2 viruses with higher titers than vaccines with wild-type H3 HA antigens. This is the first report demonstrating the effectiveness of a broadly reactive H3N3 vaccine in a preimmune ferret model. [ABSTRACT FROM AUTHOR]

Background: Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking.Methods: In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI).Results: Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001).Conclusions: Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates. [ABSTRACT FROM AUTHOR]

Abstract Background In the Southern Hemisphere 2010 influenza season, Seqirus' split-virion, trivalent inactivated influenza vaccine was associated with increased reports of fevers and febrile reactions in young children. A staged clinical development program of a quadrivalent vaccine (Seqirus IIV4 [S-IIV4]; Afluria® Quadrivalent/Afluria Quad™/Afluria Tetra™), wherein each vaccine strain is split using a higher detergent concentration to reduce lipid content (considered the cause of the increased fevers and febrile reactions), is now complete. Methods Children aged 6–59 months were randomized 3:1 and stratified by age (6–35 months/36–59 months) to receive S-IIV4 (n = 1684) or a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n = 563) during the Northern Hemisphere 2016–2017 influenza season. The primary objective was to demonstrate noninferior immunogenicity of S-IIV4 versus C-IIV4. Immunogenicity was assessed by hemagglutination inhibition (baseline, 28 days postvaccination). Solicited, unsolicited, and serious adverse events were assessed for 7, 28, and 180 days postvaccination, respectively. Results S-IIV4 met the immunogenicity criteria for noninferiority. Adjusted geometric mean titer ratios (C-IIV4/S-IIV4) for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 0.79 (95% CI: 0.72, 0.88), 1.27 (1.15, 1.42), 1.12 (1.01, 1.24), and 0.97 (0.86, 1.09), respectively. Corresponding values for differences in seroconversion rates (C-IIV4 minus S-IIV4) were −10.3 (−15.4, −5.1), 2.6 (−2.5, 7.8), 3.1 (−2.1, 8.2), and 0.9 (−4.2, 6.1). Solicited, unsolicited, and serious adverse events were similar between vaccines in both age cohorts, apart from fever. Fever rates were lower with S-IIV4 (5.8%) than C-IIV4 (8.4%), with no febrile convulsions reported with either vaccine during the 7 days postvaccination. Conclusion S-IIV4, manufactured with a higher detergent concentration, demonstrated noninferior immunogenicity to the US-licensed C-IIV4, with similar postvaccination safety and tolerability, in children aged 6–59 months. This completes the program demonstrating the immunogenicity and safety of S-IIV4 in participants aged 6 months and older. Funding Seqirus Pty Ltd; ClinicalTrials.gov identifier: NCT02914275. [ABSTRACT FROM AUTHOR]

Abstract Since 2017, a new type of goose-origin astrovirus (GoAstV) disease occurred in China. This disease can cause joint swelling of sick geese, and the anatomy shows a clear urate precipitation in the viscera. The rate of death or amputation can reach more than 30%, revealing its severe pathogenicity. One novel goose-origin astrovirus strain, designated as CXZ18, was isolated from diseased geese with a fatal infection characterized by visceral urate deposition. Similar clinical anatomy symptoms were partially reproduced by attacking infection of healthy geese. The CXZ18 has no hemagglutination with chicken erythrocyte, only reproduced in goose embryos, not in SPF chicken or duck embryos. The complete genome-encoded three open reading frames (ORFs) of CXZ18 were 7252 nt in length. BLAST-based homology analysis of viral complete genome showed that CXZ18 has only 53.0%–61.8% with other classic avian astrovirus from various hosts. Further analysis of ORF 1a, ORF 1b, and ORF 2 genes revealed that the isolate was genetically distinct from known astroviruses and belonged to a distinctive branch of avian astroviruses. To conclude, a naturally occurring novel nephrotic astrovirus, distinguished with all previously reported avian astroviruses, was derived from goose [ABSTRACT FROM AUTHOR]

Highlights • Pre-exposure with 1933 influenza A virus offers substantial cross-protection against both contemporary H1N1 and H3N2 subtypes in pigs. • The observed cross-subtype protection is not mediated by traditional serum neutralizing antibodies. Abstract There is an urgent need to develop a broad-spectrum vaccine that can effectively prevent or eliminate the spread of co-circulating swine influenza virus strains in multiple lineages or subtypes. We describe here that pre-exposure with a live virus generated via a A/WSN/1933(H1N1) reverse genetics system resulted in a significant reduction of viral shedding from pigs exposed to either a swine H1N1 virus or a swine H3N2 virus. At 3-day post challenge (DPC), approximately 1 log and 1.5 logs reductions of viral shedding were observed in the swine H1N1- and H3N2-challenged vaccinated pigs when compared to unvaccinated animals. A further decline in viral load was observed at 5 DPC where viral shedding was decreased by greater than 3 logs in vaccinated pigs receiving either the H1N1 or H3N2 virus challenge. Although the sera of the vaccinated pigs contained high titers of neutralizing antibodies against the vaccine strain, measured by Hemagglutination Inhibition (HI) assay, only suboptimal HI titers of neutralizing antibody were detected in the post-challenge serum of the vaccinated animals using the challenge swine H1N1 virus. The substantial genetic and antigenic differences between the vaccine virus and the challenge viruses imply that the observed protection may be mediated by mechanisms other than neutralization by IgG, such as non-neutralizing antibody activities, mucosal immunity, or conserved T cell immunity, which warrants further investigation. [ABSTRACT FROM AUTHOR]

In the present study, a trail to evaluate of Newcastle Disease (ND) antibodies levels after different vaccination programs was conducted on layer chickens. A total of 200 one day-old layer chicks (White Lohmann) were divided into five groups A, B, C, D and E. Birds in groups A, B and C were vaccinated with live vaccine by intraocular, intranasal and drinking water methods , respectively. On the other hand, groups D and E were kept as unvaccinated control groups. Vaccination performed at days 5, 18 and 28 by different routes for mentioned groups. Hemagglutination inhibition (HI) and enzyme-linked immunosorbent assay (ELISA) methods were used for assessment of antibodies titer at days 15, 25, 37 and 45. Results of HI and ELISA tests indicated that, the intranasal and the intraocular method have highest antibodies titers compared with the drinking water method. In this study, maternally derived antibodies specific to Newcastle Disease Virus (NDV) (IgY) were extracted by dextran sulfate method from collected eggs of vaccinated laying chickens . Antibodies specific to NDV (IgY) were detected in the egg yolk using HI test . Data revealed that antibodies specific to NDV (IgY) were presented in high titers that confer protection during early weeks of life for hatching chicks. Data concluded that extraction of maternally derived specific antibodies from egg yolk will facilitate accurate monitoring of ND vaccination programmes. [ABSTRACT FROM AUTHOR]

Fresh kidney beans (Phaseolus vulgaris L.) are common green vegetable that are widely cultured and consumed worldwide. The benefits of fresh kidney beans are highly substantial, but at the same time, toxicity caused by phytohemagglutinin (PHA) has raised concerns. PHA from fresh kidney beans accounted for 40% of poisoning events induced by poisonous plants in China from 2004 to 2013. However, an understanding of PHA levels in fresh kidney beans remains elusive. An analysis method for PHA based on agglutination of PHA to erythrocyte cell was established. We investigated the effect of cultivar, bean part, maturity, and cooking method on PHA content in fresh kidney beans. We demonstrated significant differences in the distribution of PHA among various predominant, fresh Chinese kidney bean cultivars and parts. One major Chinese strain, Zihuayoudou, was found to contain the highest amount of PHA, which was abundant in fresh kidney bean seeds. Moreover, PHA concentrations were found to decrease with the maturity of the fresh product. Further, cooking methods had a significant effect on PHA levels in fresh kidney beans. PHA could be effectively removed when stir-frying for more than 18 min, or braising for more than 10 min. These findings provide insight into the PHA content of fresh kidney beans in China and will be helpful to guide food safety measures. [ABSTRACT FROM AUTHOR]

Background Mumps vaccine immunizations have reduced the incidence of this disease. With the variation of mumps circulating strain, novel vaccine strains are always important. Methods A 2-center parallel, randomized, double-blind noninferiority trial was performed to compare an F-genotype attenuated mumps vaccine (SP strain) to the A-genotype vaccine (S-79, Jeryl-Lynn strain) in 1080 healthy children aged 8–24 months in Hubei, China. Results Participants were randomly assigned to receive a high or low dose of the SP or S79 vaccine and then assessed clinically at 30 minutes and 1–28 days postinoculation. No differences in local or systemic reactivity were observed. A similar incidence of severe adverse events associated with the vaccine was observed in the high-dose group and the positive control group. Based on throat swab collections, no viral shedding was present at the 4th and 10th days in any group. Neutralizing and hemagglutination-inhibiting antibody assays with the F- or A-genotype strains showed similar trends in geometric mean titers in the high-dose SP and S79 groups. Increased cytotoxic T lymphocyte responses were observed in all groups. Conclusions The F-genotype attenuated mumps vaccine is safe, offers immunogenicity against a homologous virus, and is noninferior to the A-genotype vaccine in 8- to 24-month-old children. [ABSTRACT FROM AUTHOR]

Copyright of Archives of Razi Institute is the property of Institut Razi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: We previously reported that despite HIV-infected pregnant women had modest humoral immune responses to inactivated influenza vaccine (IIV) measured by hemagglutination-inhibition (HAI) assay, the observed vaccine efficacy against influenza disease was higher than predicted by HAI; suggesting that IIV may confer protection to HIV-infected individuals by additional mechanisms. We evaluated the response to IIV by microneutralization (MN) and HAI assays and correlated both methods in HIV-infected and HIV-uninfected pregnant women. Methods: MN and HAI antibodies were measured pre-vaccination and approximately one-month post-vaccination in 80 HIV-infected and 75 HIV-uninfected women who received IIV. Geometric mean titers (GMTs), fold-change in titers and seroconversion rates were determined for the three influenza stains in the vaccine. Results: After vaccination there were significant increases in MN and HAI GMTs for the three vaccine strains in both HIV-infected and HIV-uninfected women. HIV-infected women had, however, a lower immune response compared to HIV-uninfected. Fold-increases were 2 to 3-times higher for MN assay compared to HAI assay for the influenza-A strains. Also a higher percentage of women seroconverted by MN than by HAI assay for the influenza-A strains. There was high positive correlation between MN and HAI assays, except for the B/Victoria strain at pre-vaccination. Conclusions: In general, the MN assay was more sensitive than the HAI assay. Microneutralization antibodies might correlate better with protection against influenza infection. [ABSTRACT FROM AUTHOR]

Abstract Background In the United States, seasonal inactivated influenza vaccine (IIV) is recommended for pregnant women; however, in early 2009, immunization rates were low, partly due to limited prospective data and concerns about vaccine safety. Objective We conducted a randomized study of two licensed seasonal trivalent IIVs (IIV3) to assess their safety and immunogenicity in pregnant women. Study Design In this prospective, randomized clinical study, 100 pregnant women, 18–39 years of age and ≥14 weeks gestation received a single intramuscular dose of 2008–2009 Fluzone® or Fluarix®. Injection site and systemic reactions were recorded for 7 days after vaccination and serious adverse events (SAEs) and pregnancy outcomes were documented. Serum samples collected before and 28 days after vaccination were tested for hemagglutination inhibition (HAI) antibody levels. Results The majority of the injection site and systemic reactions were mild and self-limited after both vaccines. No fever ≥100 °F was reported. There were no vaccine-associated SAEs. Immune responses to influenza vaccine antigens were similar for the two study vaccines, with robust HAI responses against influenza A strains, and relatively lower responses for influenza B strains. Conclusion Seasonal inactivated influenza vaccines were well tolerated and immunogenic in pregnant women. ClinicalTrials.gov identifier NCT00905125. Synopsis: In this prospective clinical trial, we demonstrated that immunization with seasonal trivalent, inactivated influenza vaccine in the second and third trimester of pregnancy is immunogenic and safe. [ABSTRACT FROM AUTHOR]

Herein, the chemical synthesis and binding analysis of functionalizable rigid and flexible core trivalent sialosides bearing oligoethylene glycol (OEG) spacers interacting with spike proteins of influenza A virus (IAV) X31 is described. Although the flexible Tris‐based trivalent sialosides achieved micromolar binding constants, a trivalent binder based on a rigid adamantane core dominated flexible tripodal compounds with micromolar binding and hemagglutination inhibition constants. Simulation studies indicated increased conformational penalties for long OEG spacers. Using a systematic approach with molecular modeling and simulations as well as biophysical analysis, these findings emphasize on the importance of the scaffold rigidity and the challenges associated with the spacer length optimization. The rigid adamantane‐based trivalent sialoside with optimized oligoethylene glycol spacer was found to be the most potent candidate against IAV/X31, showing an inhibitory constant in the micromolar range. It binds to hemagglutinin of the influenza virus and thus inhibits the virus–cell attachment. [ABSTRACT FROM AUTHOR]

Influenza virus neuraminidase (NA) can act as a receptor-binding protein, a role commonly attributed to hemagglutinin (HA). In influenza A(H3N2) viruses, three NA amino acid residues have previously been associated with NA-mediated hemagglutination: T148, D151, and more recently, H150. These residues are part of the 150-loop of the NA monomer. Substitutions at 148 and 151 arise from virus propagation in laboratory cell cultures, whereas changes at 150 occurred during virus evolution in the human host. In this study, we examined the effect of natural amino acid polymorphism at position 150 on NA-mediated hemagglutination. Using the A/Puerto Rico/8/34 backbone, we generated a comprehensive panel of recombinant A(H3N2) viruses that have different NAs but shared an HA that displays poor binding to red blood cells (RBCs). None of the tested substitutions at 150 (C, H, L, R, and S) promoted NA-binding. However, we identified two new determinants of NA-binding, Q136K and T439R, that emerged during virus culturing. Similar to T148I, both Q136K and T439R reduced NA enzyme activity by 48–86% and inhibition (14- to 173-fold) by the NA inhibitor zanamivir. NA-binding was observed when a virus preparation contained approximately 10% of NA variants with either T148I or T439R, highlighting the benefit of using deep sequencing in virus characterization. Taken together, our findings provide new insights into the molecular mechanisms underlying the ability of NA to function as a binding protein. Information gained may aid in the design of new and improved NA-targeting antivirals. • Substitutions Q136K and T439R are newly identified determinants of NA-mediated hemagglutination. • NA substitutions at 136 and 439 reduced enzyme activity and inhibition by zanamivir. • NA-mediated binding occurred when T439R was present as a minor population (∼10%) in a virus preparation. • Natural amino acid polymorphism at residue 150 was not associated with NA-mediated binding. [ABSTRACT FROM AUTHOR]

As alloantibodies are expected to bind to transfused erythrocytes and lead to agglutination before free unbound alloantibodies are found in recipient plasma, it makes it even less likely that unbound alloantibodies could be detected in a crossmatch test so early posttransfusion. Such reactions are completely different from alloantibody responses induced by transfusion of canine blood with an incompatible blood type and clinicians should not automatically conclude that unspecific minor agglutination reactions are clinically relevant, as this would deter transfusion of animals in need of life-saving transfusions. Dr Barbara Kohn's group at the Clinic for Small Animals of the Freie University Berlin, Germany, recently reported on crossmatch results in (pre-) transfused dogs in I JVIM i .[1] These authors used a tube crossmatch method without canine antiglobulins to assess the potential appearance of alloantibodies posttransfusion. [Extracted from the article]

The 2 predominant circulating subtypes of influenza A virus in the dog population, equine-origin H3N8 and avian-origin H3N2, constitute a potential zoonotic risk. We determined the prevalence of influenza A antibodies in 496 dogs in Poland and found 2.21% of sera positive by commercial ELISA. Hemagglutination inhibition (HI) assays indicated 7.25% of sera positive using equine H3N8, swine H3N2, and pandemic H1N1 antigens, with the most frequently detected immune response being to H3N2. Considering interspecies transfer, reassortment ability, and close contact between dogs and humans, infections of dogs with influenza A virus should be monitored. [ABSTRACT FROM AUTHOR]

Influenza B virus-caused illness has recently been considered as an urgent public health problem due to substantial morbidity, mortality and life-threatening medical complications. In this study, we have reported the main characteristics of influenza B virus in Mongolia, including prevalence, lineages, suitability with vaccine strains and drug susceptibility against the virus. 15768 specimens were tested by qPCR for detecting influenza viruses. From positive specimens for influenza B virus, the clinical isolates were isolated using MDCK cells. Sequencing analysis, hemagglutination inhibition assay and Neuraminidase inhibitor (NAI) drug susceptibility testing were performed for the clinical isolates. Influenza B virus was around in 3.46% of the samples in Mongolia, and B/Victoria clade-1A and B/Yamagata clade-3 lineages were predominant. Importantly, it was confirmed that the lineages corresponded to the vaccine strains. Moreover, drug susceptibility tests revealed that some Mongolian clinical isolates showed reduced susceptibility to antiviral agents. Interestingly, G104R was identified as a novel mutation, which might have a significant role in drug resistance of the virus. These results describe the characteristics of influenza B viruses that have caused respiratory illness in the population of Mongolia between 2013 and 2017. [ABSTRACT FROM AUTHOR]

Outbreaks of the highly pathogenic avian influenza H5N1 and H7N9 viruses have spurred an unprecedented research effort to develop antivirals and vaccines against influenza. Standardized methods for vaccine evaluation are critical for facilitating vaccine development. Compared with hemagglutination inhibition assays, mounting evidence suggest that microneutralization tests (MNTs) is a better choice for the evaluation of candidate pandemic influenza vaccines because they measure neutralizing antibody activity in cell cultures and are more sensitive in detecting H5 and H7. Here, we report a MNT measuring neuraminidase activity as the read-out (NA-MNT) for quantitative analysis of neutralizing antibodies against avian influenza viruses. Compared to the conventional microneutralization assay (ELISA-MNT), the NA-MNT is faster with lower intra- and inter-assay variations, while no difference in geometric mean titers was found between these two assays for the evaluation of H5N1 and H7N9 vaccines. These results suggest that NA-MNT is a reliable and high throughput method which could facilitate the development of candidate pandemic influenza vaccine. [ABSTRACT FROM AUTHOR]

Abstract The generation of virus-mimetic nanoparticles has received much attention in developing a new vaccine for overcoming the limitations of current vaccines. Thus, a method, encompassing most viral features for their size, hydrophobic domain and antigen display, would represent a meaningful direction for the vaccine development. In the present study, a polymer-templated protein nanoball with direction oriented hemagglutinin1 on its surface (H1-NB) was prepared as a new influenza vaccine, exhibiting most of the viral features. Moreover, the concentrations of antigen on the particle surface were controlled, and its effect on immunogenicity was estimated by in vivo studies. Finally, H1-NB efficiently promoted H1-specific immune activation and cross-protective activities, which consequently prevented H1N1 infections in mice. Graphical abstract Image 1 [ABSTRACT FROM AUTHOR]

Background: Although ferret antisera used in influenza surveillance did not detect antigenic drift of A(H1N1)pdm09 viruses during the 2015-2016 season, low vaccine effectiveness was reported in adults. We investigated the immune basis of low responses to circulating A(H1N1)pdm09 viruses after vaccination.Methods: Prevaccination and postvaccination serum samples collected from >300 adults (aged 18-49 years) in 6 seasons (2010-2011 to 2015-2016) were analyzed using hemagglutination inhibition assays to evaluate the antibody responses to 13 A(H1N1) viruses circulated from 1977 to 2016. Microneutralization and serum adsorption assays were used to verify the 163K and 223R specificity of antibodies.Results: Individual antibody profiles to A(H1N1) viruses revealed 3 priming patterns: USSR/77, TW/86, or NC/99 priming. More than 20% of adults had reduced titers to cell-propagated circulating 6B.1 and 6B.2 A(H1N1)pdm09 viruses compared with the A/California/07/2009 vaccine virus X-179A. Significantly reduced antibody reactivity to circulating viruses bearing K163Q was observed only in the USSR/77-primed cohort, whereas significantly lower reactivity caused by egg-adapted Q223R change was detected across all 3 cohorts.Conclusion: Both 163K specificity driven by immune priming and 223R specificity from egg-adapted changes in the vaccine contributed to low responses to circulating A(H1N1)pdm09 viruses after vaccination. Our study highlights the need to incorporate human serology in influenza surveillance and vaccine strain selection. [ABSTRACT FROM AUTHOR]

Hemagglutination inhibition (HI) titers are a major correlate of protection for influenza-related illness. The influenza virus hemagglutinin possesses antigenic sites that are the targets of HI active antibodies. Here, a panel of mutant viruses each lacking a classically defined antigenic site was created to compare the species-specific immunodominance of the antigenic sites in a clinically relevant hemagglutinin. HI active antibodies of antisera from influenza virus-infected mice targeted sites Sb and Ca2. HI active antibodies of guinea pigs were not directed against any specific antigenic site, although trends were observed toward Sb, Ca2, and Sa. HI titers of antisera from infected ferrets were significantly affected by site Sa. HI active antibodies of adult humans followed yet another immunodominance pattern, in which sites Sb and Sa were immunodominant. When comparing the HI profiles among different species by antigenic cartography, animals and humans grouped separately. This study provides characterizations of the antibody-mediated immune responses against the head domain of a recent H1 hemagglutinin in animals and humans. [ABSTRACT FROM AUTHOR]

Background: The immunological response to influenza vaccine and/or natural infection is evaluated by serological techniques, the most common being hemagglutination inhibition (HI), single radial hemolysis (SRH), and virus neutralization assays, which is commonly used in a micro‐neutralization (MN) format. ELISA is not officially required; however, this assay is able to measure different class‐specific antibodies. The four assays identify different sets or subsets of antibodies. Objectives: The aim of this study was to establish the correlation among four serological assays using four seasonal influenza strains. Methods: The HI, SRH, MN assays, and ELISA were performed on four seasonal influenza strains. Results: A strong positive correlation was found between HI and MN and between SRH and MN assays for influenza A strains. The B strains also showed good correlations among the three assays. A positive correlation was also found between ELISA and the "classical" assays for all strains. Concerning the correlates of protection, as defined by HI ≥ 40 and SRH ≥ 25 mm2, good agreement was observed for the influenza A strains. By contrast, the agreement for the B strains was very low. Conclusions: There is a positive strong correlation among the four serological assays for both A and B strains, especially for the HI and MN assays. There is good agreement on correlates of protection between HI and SRH assays for the A strains, but very low agreement for the B strains, suggesting higher sensitivity of SRH than HI assay in detecting antibodies against the influenza B viruses. [ABSTRACT FROM AUTHOR]

Highlights • The type of adjuvant in influenza vaccines impacted lung immunopathology with mismatched challenge virus. • Oil-in-water adjuvants induced potent homologous immune responses, but were associated with VAERD. • Adjuvanted WIV vaccines did not provide complete protection from heterologous challenge. Abstract Influenza A virus (IAV) causes a disease burden in the swine industry in the US and is a challenge to prevent due to substantial genetic and antigenic diversity of IAV that circulate in pig populations. Whole inactivated virus (WIV) vaccines formulated with oil-in-water (OW) adjuvant are commonly used in swine. However, WIV-OW are associated with vaccine-associated enhanced respiratory disease (VAERD) when the hemagglutinin and neuraminidase of the vaccine strain are mismatched with the challenge virus. Here, we assessed if different types of adjuvant in WIV vaccine formulations impacted VAERD outcome. WIV vaccines with a swine δ1-H1N2 were formulated with different commercial adjuvants: OW1, OW2, nano-emulsion squalene-based (NE) and gel polymer (GP). Pigs were vaccinated twice by the intramuscular route, 3 weeks apart, then challenged with an H1N1pdm09 three weeks post-boost and necropsied at 5 days post infection. All WIV vaccines elicited antibodies detected using the hemagglutination inhibition (HI) assay against the homologous vaccine virus, but not against the heterologous challenge virus; in contrast, all vaccinated groups had cross-reactive IgG antibody and IFN-γ responses against H1N1pdm09, with a higher magnitude observed in OW groups. Both OW groups demonstrated robust homologous HI titers and cross-reactivity against heterologous H1 viruses in the same genetic lineage. However, both OW groups had severe immunopathology consistent with VAERD after challenge when compared to NE, GP, and non-vaccinated challenge controls. None of the WIV formulations protected pigs from heterologous virus replication in the lungs or nasal cavity. Thus, although the type of adjuvant in the WIV formulation played a significant role in the magnitude of immune response to homologous and antigenically similar H1, none tested here increased the breadth of protection against the antigenically-distinct challenge virus, and some impacted immunopathology after challenge. [ABSTRACT FROM AUTHOR]

Abstract Live attenuated influenza vaccines (LAIVs) are promising tools for the induction of broad protection from influenza due to their ability to stimulate cross-reactive T cells against influenza pathogens. One of the major targets for cytotoxic T-cell immunity is viral nucleoprotein (NP), which is relatively conserved among antigenically distant influenza viruses. Nevertheless, a diversity of epitope composition has been found in the NP protein of different lineages of influenza A viruses. The H2N2 master donor virus which is currently used as a backbone for the LAIV and donor of the six genomic segments encoding the internal proteins, A/Leningrad/134/17/57 (MDV Len/17), was isolated 60 years ago. As such, NP-specific T-cell immunity induced upon vaccination with classical LAIVs with a 6:2 genome composition containing this older NP might be suboptimal against currently circulating influenza viruses. In this study, a panel of H3N2 LAIV candidates with wild-type NP genes derived from circulating viruses were generated by reverse genetics (5:3 genome composition). These viruses displayed the cold adaptation and temperature sensitivity phenotypes of MDV Len/17 in vitro. LAIVs with both 6:2 and 5:3 genome compositions were attenuated and replicated to a similar extent in the upper respiratory tract of ferrets. LAIVs were immunogenic as high neutralizing and hemagglutination inhibition serum antibody titers were detected 21 days after infection. All vaccinated animals were protected against infection with heterologous H3N2 influenza A viruses. Thus, LAIV with a 5:3 genome composition is safe, immunogenic and can induce cross-protective immunity. Highlights • Classical LAIVs might induce suboptimal NP-specific T-cell responses against recent influenza viruses; • A panel of H3N2 LAIV candidates with wild-type NP genes were compared to classical 6:2 LAIVs in ferrets; • Wild-type NP gene does not affect the safety profile of H3N2 LAIVs; • LAIVs with wild-type NP genes induced cross-reactive antibody immune responses similar to classical LAIVs; [ABSTRACT FROM AUTHOR]

Blood type in saliva can be examined through bitemarks on an object left at the crime scene in a crime case as a screening test of suspected perpetrators. Saliva deposited at the bite contains glycoproteins which can carry blood type ABH antigens expressed in the salivary glands and excreted in saliva. Salivary examination is influenced by various external factors that damage saliva, one of which is the duration of exposure to room temperature in a certain period of time. This study aimed to determine differences in protein levels and blood group agglutination titers in (Pyrus bretschneideri) pear bitemark saliva during room temperature exposure within 30, 60 and 90 minutes. This type of study was experimental laboratories with time series design. The samples used were 18 pear bitemarks from 6 individuals who had blood groups A, B and AB then incubated for 30, 60 and 90 minutes. Analysis of protein content using trizol reagent was determined spectrophotometrically, while blood group examination used inhibition absorption method. Anova test showed significant difference between groups of 30 minutes exposure duration with 60 minutes and 90 minutes exposure group (P<0.05; 95% confidence interval). The Pearson correlation obtained the results of -0.739, indicating correlation that the longer exposure to room temperature, the lower the protein content. The results showed that there was a decrease in salivary protein levels and blood group agglutination titers. Salivary protein levels were still detected in the time range of 30, 60 and 90 minutes, so that blood type can still be examined from saliva in bitemarks on pear fruit. [ABSTRACT FROM AUTHOR]

Bovine lactoferrin C-lobe is able to prevent both influenza virus hemagglutination and cell infection. In particular, it was demonstrated that the fragment 418SKHSSLDCVLRP429 is a potent antiviral peptide. Therefore, we tried to increase the stability of this fragment through side-chain lactam cyclization of the peptide, S[KHSSLD]CVLRP (1). However, classic strategy involving solid-supported cyclization of the linear precursor, containing orthogonal allyl/alloc-based protection for the key amino and carboxyl residues, did not provide the desired cyclic peptide. Here, we report the identification of problematic stretches during the sequence assembly process and the optimization of the different parameters involved in the construction of 1. Results indicated a significant influence of β-protecting group of both aspartic acid and adjacent cysteine residues on the formation of side products. Therefore, the identification of suitable β-protecting groups of these residues allowed us to optimize the synthesis of designed lactam-bridged cyclic peptide. [ABSTRACT FROM AUTHOR]

The aim of this study was the isolation, identification and molecular characterization of Avian (Pigeon) Paramyxovirus-1 (APMV-1) isolated from clinically affected pigeons suspected to be infected with PPMV-1 in Egypt between 2016 and 2017. Twenty-five field samples were collected and inoculated into the allantoic cavity of ECE. Allantoic fluids were tested for haemagglutinating (HA) activity followed by haemagglutination inhibition (HI) test for virus identification. Molecular confirmation was done by reverse transcription polymerase chain reaction (RT-PCR) using primers specific to the fusion (F) gene. Results revealed 12 out of 25 positive samples. Two samples were selected for sequencing and phylogenetic analysis which revealed that two different amino acid motifs were found at the cleavage site of F protein: 112 KRQKRF117 (associated with virulent strains) and 112GRQGRL117 (associated with lentogenic strains).To our knowledge, this is the first reported PPMV-1 isolates that possess the sequences of 112GRQGRL117 within the F0 protein. [ABSTRACT FROM AUTHOR]

Hypothiocyanite (OSCN-) is a natural component of human saliva and is produced by the lactoperoxidase (LPO)/thiocyanate/hydrogen peroxide (H2O2) system. OSCN- has been previously shown to exhibit antiviral activity against influenza viruses (IFV) A/H1N1/2009 and A/H1N2/2009 in vitro as well as antimicrobial and antifungal activities. We elucidated the antiviral activity of OSCN- against both IFV types A and B and the mode of its antiviral action. OSCN- was produced constantly at 900 ± 200 µmol/l in Na3PO4 buffer solution containing NaSCN and LPO in the presence of H2O2 as an original OSCN- solution. In a plaque reduction assay, IFV A/PR/8/34 (H1N1), A/Fukushima/13/43 (H3N2), B/Singapore/222/97, and B/Fukushima/15/93 were exposed to various concentrations of OSCN- for 0 to 30 min before adsorption to MDCK cells, and plaque formation was examined. OSCN- exhibited significant similar antiviral activities against all four viruses without cytotoxicity, and the EC50 values for them were from 57 ± 16 to 148 ± 27 µmol/l regardless of the exposure times. The exposure of MDCK cells to OSCN- before viral adsorption did not affect its anti-IFV activity (EC50: more than 450 µmol/l), but the exposure after viral adsorption affected it moderately (EC50: 380 ± 40 µmol/l). Moreover, the exposure of virus particles to OSCN- at 450 µmol/l did not affect the hemagglutinin activity of IFV in hemagglutination inhibition assay. These results suggest that the attachment of OSCN- to the viral envelope critically contributes to the mode of antiviral action of OSCN- without interfering with viral adsorption. [ABSTRACT FROM AUTHOR]

Probability-based surveys of the application of chitosan succinate as an adjuvant added to the vaccine against animal necrobacteriosis have been performed. The addition of 3.7% chitosan succinate (MM 330 kDa) to the standard-dose vaccine formulation could contribute to improvement of the vaccine immunogenicity, as measured by the hemagglutination test (HA): 1 : 512 as compared to 1 : 128 in the control range. The use of 0.5-% chitosan succinate solution as a protective medium for drying in the production of a dried inactivated vaccine against infectious bovine rhinotracheitis could ensure the preservation of the biopreparation’s high immunogenic activity. Chitosan succinate was shown to have quite good solubility in water, allowing the possible use of saline solution to reconstitute the vaccine into the suspension for injection and to abandon expensive solvents. [ABSTRACT FROM AUTHOR]

The present study was carried out in the region of South Gujarat, India, to determine the prevalence and predisposing factors of canine parvovirus-2 (CPV-2) infection in acute gastroenteritis of pups. Further, haemagglutination (HA) test, enzyme linked immunosorbent assay (ELISA), polymerase chain reaction (PCR) and rapid immunochromatography test were compared for diagnosis and prevalent CPV-2 types were ascertained. A total of 73 diarrhoea samples were collected and out of those 32, 33 and 35 were found positive via HA, ELISA and PCR, respectively. In rapid test, 26/52 samples were found positive. Among different agegroups, 11/24 and 13/21 animals were positive in pups aged 4-8 and 8-12 weeks, respectively. All but one (34/35) positive samples were from unvaccinated animals. Labrador was found to be the most susceptible breed (n = 13) to infection. Considering PCR as the best test, 47.94% (35/73) prevalence of CPV was recorded. Among PCR positive samples, 3 and 32 belonged to type CPV-2a and CPV-2b, respectively. Type CPV-2c was not detected among the examined samples. Sequencing analysis of 9/10 CPV-2b isolates revealed single nucleotide polymorphism (SNP) (A-G) at position 4106 (alanine to threonine) and suggested the occurrence of mutant, new CPV-2b in this area. As other major pathogen canine coronavirus was detected in 7/38 CPV negative samples. Conclusively, CPV-2 infection was detected in 47.97% cases of AGE of pups which warrants search for other pathogens in the diagnostic procedure. This work is among the few recent reports which depict the occurrence of a novel mutant (new CPV-2b) in India. [ABSTRACT FROM AUTHOR]

Background: The active components of natural products provide a potential alternative to conventional immunotherapy for a variety of diseases conditions and become subject to scientific investigations currently worldwide. Objective: The purpose of this research was to investigate the immunostimulatory activity of the chitosan nanoparticle on Wistar albino rats. Materials and Methods: The present investigation was carried out on various groups of healthy adult rats. The assessment of immunomodulatory potential was carried out by neutrophil adhesion test, delayed-type hypersensitivity (DTH) response, haemagglutinating antibody (HA) titre, cyclophosphamide-induced myelosuppression and phagocytic activity were determined in various groups of animals. Results: The administration of chitosan nanoparticle at doses 300 mg/kg BW and 600 mg/kg BW but not at doses 150 mg/kg BW significantly increased in neutrophil adhesion fibers, haemagglutinating antibody titre values and potentiated the inhibited type hypersensitivity reaction induced by sheep red blood cells. Also, it had good response towards phagocytosis in carbon clearance assay and prevented myelosuppression of cyclophosphamide on rats. Conclusion: From these findings, it can be concluded that chitosan nanoparticle responsible for immunostimulatory activity and has therapeutic potential for the prevention of immune depressed conditions. [ABSTRACT FROM AUTHOR]

Highlights • Three serological assays were used to analyse samples from 509 racehorses • Only 69.9% of Moroccan racehorses have protective levels of SRH antibody • The brand of EI vaccines used had a weak influence on the serological status • The level of EI protective antibody remains a concern despite mandatory EI vaccination Abstract In order to evaluate the vaccination status against equine influenza (EI) in Moroccan racehorses, a serological investigation was carried out on 509 racehorses using three serological tests: an Enzyme-Linked Immunosorbent Assay (ELISA), the Hemagglutination Inhibition (HI) test and the Single Radial Haemolysis (SRH) assay. The serological analysis showed 56% of seropositivity by ELISA, 67% by HI and 89.4% by SRH (with 69.9% above the clinical protection threshold). Using the Kappa test, the SRH and HI assays showed a strong agreement, the SRH and ELISA assays had a moderate agreement and the HI and ELISA assays showed a poor agreement. Seropositivity was positively correlated with the age of horses and the number of immunisation received. EI vaccines used during the last immunisation before the study had a weak influence on the serological status. This effect was observed when the vaccines Calvenza and Fluvac Innovator® were used, with 94.1% and 100% of seropositivity when measured by HI, and with 100% and 94.7% exceeding the clinical protection threshold when measured by SRH, respectively. No effect was found when other EI vaccines, including Prequenza-Te® (67% coverage (342/509) and Proteqflu-Te® (22% coverage (114/509) were used; with 64% and 67.5% seropositivity (HI) and with 66.4% and 72.8% above the clinical threshold (SRH), respectively. The location and the time since last vaccination have no influence on the serological result. Overall, levels of protective antibody against EI in Moroccan racehorses remain a concern despite mandatory vaccination. [ABSTRACT FROM AUTHOR]

Highlights • We generated a novel chimeric H7/H5 virus expressing HA1 of the H7N9 virus and HA2 of the H5N6 virus. • The chimeric PR8-H7/H5 induced cross-reactive hemagglutination inhibition antibodies against H7 virus only. • The chimeric PR8-H7/H5 induced serum-neutralizing antibodies against both H7 and H5 viruses. • The chimeric PR8-H7/H5 significantly reduced virus shedding in immunized chickens. • The chimeric PR8-H7/H5 protected chickens against lethal challenge with H7N9 and H5N6 viruses. Abstract The highly pathogenic avian influenza (HPAI) H5 and H7N9 viruses pose a serious challenge to public health and the poultry industry in China. In this study, we generated a chimeric H7/H5 recombinant virus that expressed the entire HA1 region of the HPAI A/chicken/Guangdong/RZ/2017(H7N9) virus and the HA2 region of the HPAI A/chicken/Fujian/5/2016(H5N6) viruses. The resulting chimeric PR8-H7/H5 virus exhibited similar growth kinetics as the parental PR8-H5 and PR8-H7 viruses in vitro. The inactivated chimeric PR8-H7/H5 vaccine induced specific, cross-reactive hemagglutination inhibition antibodies against the H7 virus only but induced serum-neutralizing antibodies against both H7 and H5 viruses. Furthermore, the inactivated chimeric PR8-H7/H5 vaccine significantly reduced virus shedding and protected chickens from challenge with the HPAI H5N6 and H7N9 viruses. Our results suggested that the inactivated chimeric PR8-H7/H5 vaccine was effective against HPAI H5 and H7N9 viruses in chickens. [ABSTRACT FROM AUTHOR]

Birds (364) of both sexes, 11-wk-old, belonging to 2 native (Brown Nicobari and Ghagus) breeds and 1 exotic breed (Dahlem Red) were evaluated for cell-mediated immune response (CMI) by phytohemagglutinin-P (PHA-P), hemagglutination inhibition (HI) assay against Newcastle disease virus (NDV) antigen (LaSota stock virus), flow cytometric analysis of CD8+ cytotoxic T lymphocytes (CTLs), and hematology and biochemical assays. The cutaneous basophil hypersensitivity response PHA-P% increase in wattle thickness (mm) was highest in Ghagus (431.14 ± 22.56) which differed significantly with that of Brown Nicobari (269.1 ± 22.66) and Dahlem Red (218.42 ± 22.30). Sex-wise observation showed that females are having significantly higher response than males. Hemagglutination inhibition test was performed to determine the serum antibodies against Newcastle disease (ND) virus. Brown Nicobari showed highest HI antibody titer than Ghagus and Dahlem Red to similar vaccination program after booster NDV dose. Flow cytometry assay revealed significantly higher CTLs proliferation in Brown Nicobari than Ghagus and Dahlem Red. Moreover, CTLs were found to be higher in control group than the treatment group. Other hematological parameters (103/μL) significant difference was found in white blood cell count between Dahlem Red (38.41 ± 1.03) with that of Brown Nicobari (35.28 ± 1.04) and Ghagus (34.57 ± 1.04) in treatment groups. Same trend was observed in the Lymphocyte treatment group. However, in Granulocyte treatment group, Brown Nicobari (11.04 ± 0.35) was found to be significantly different from Dahlem Red (8.68 ± 0.34) and Ghagus (9.27 ± 0.35). Correlations between body weight at 11 wk of age and CMI, HI, cytotoxic T cell were −0.093, 0.047, and −0.036, respectively. Egg weight was found to be positively correlated with that of chick weight. Serum biochemical values showed that Dahlem Red was having significantly higher creatinine levels compared to Ghagus. Triglycerides level was also significantly higher in Ghagus compared to Dahlem Red. No significant breed effect was observed for alkaline phosphate, aspartate transaminase, and alanine transaminase. Cholesterol and total serum protein levels were significantly higher in Dahlem Red compared to Brown Nicobari. [ABSTRACT FROM AUTHOR]